Magnesium in Liver Cirrhosis

Phase 4

• Conditions: LIVER CIRRHOSIS
• Interventions: Dietary Supplement: magnesium; Dietary Supplement: Placebo

• Registration Number: NCT01894867
• Lead Sponsor: Meir Medical Center

Brief Summary

Several studies have shown in patients magnesium deficiency with liver cirrhosis.

Patients with liver cirrhosis showed considerably reduced muscle strength and muscle magnesium.

We suggest addition of magnesium to patients with established cirrhosis in order to reduce the neuromuscular and neuropsychiatric manifestations of chronic liver disease.

Detailed Description

Magnesium is the fourth most abundant cation in the body and plays an important physiological role in many of its functions.

There are no readily available and easy methods to assess magnesium status but it is estimated that magnesium deficiency is a common problem.

Magnesium deficiency can cause a wide variety of features including hypocalcaemia, hypokalaemia and cardiac and neurological manifestations. Chronic low magnesium state has been associated with a number of chronic diseases including diabetes, hypertension, coronary heart disease, and osteoporosis.

There are not enough studies on magnesium status in chronic cirrhotics who may be in depletion. However , several studies have shown in patients magnesium deficiency with liver cirrhosis. Patients with liver cirrhosis showed considerably reduced muscle strength and muscle Mg . Magnesium may have a role in the neuromuscular and neuropsychiatric manifestations of chronic liver disease (hepatic encephalopathy and muscle cramps).

The use of magnesium as a therapeutic agent in asthma, myocardial infarction, and pre-eclampsia is also discussed. We suggest addition of magnesium to patients with established cirrhosis in order to reduce the neuromuscular and neuropsychiatric manifestations of chronic liver disease.

Study Timeline

• Status Verified: 2013-06
• Study First Submitted: 2013-07-04
• Study First Submitted QC: 2013-07-09
• Study First Posted: 2013-07-10
• Last Update Submitted: 2013-07-11
• Last Update Posted: 2013-07-12
• Study Start: 2013-08
• Primary Completion: 2014-04

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• patients with liver cirrhosis

Exclusion Criteria

• pregnant women
• Patients with acute or chronic renal failure (cr>1.5)
• Congestive heart failure NYHA 3-4
• Patient with active cancer
• Patients with dementia or mental retardation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
magnesium	magnesium	will get magnesium for 6 weeks
placebo	Placebo	will get placebo for 6 weeks

Primary Outcome Measures

Name	Time	Method
change in minimal hepatic encephalopathy	6 weeks

Secondary Outcome Measures

Name	Time	Method
change in muscle weakness	6 weeks after intervention

Trial Locations

Locations (1)

liver outpatients clinic, Meir medical center; 🇮🇱 Kfar Saba, Israel